Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-86
SponsorIRCCS Centro Neurolesi Bonino Pulejo

About this trial

Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 50 and 86 years.

Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI).

Referral to the neuropsychology clinic for initial assessment or clinical monitoring.

Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires.

Disqualifiers

Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases).

Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression).

Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments.

Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation.

Trial population

151

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • none - observational study

    Other intervention

    none - observational study

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Dementia or Mild Cognitive Impairment (MCI) with ADL

The primary outcome variable considered for calculation is the score of the Activities of Daily Living (ADL) scale, used as the main index of functional autonomy in subjects with dementia or mild cognitive impairment (MCI).

Time frame
12 MONTHS

Secondary outcomes

1

Functional autonomy in instrumental activities measured with the Instrumental Activities of Daily Living (IADL) scale

Assessment of functional autonomy in instrumental activities of daily living in subjects with dementia or mild cognitive impairment (MCI) using the Instrumental Activities of Daily Living (IADL) scale.

Time frame
12 MONTHS

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.